It’s one thing to get hit by weak demand, a bad quarter, or a sour tape. It’s another to get blindsided by the rulebook.
This company just launched a dirt-cheap weight-loss pill, watched the spotlight turn into a heat lamp, and pulled the plug almost immediately. The market’s not debating growth anymore. It’s debating permission.
Big Winners (Sponsored)
Most investors are happy with “nice” gains. But a small group of stocks can deliver far more.
After filtering through thousands of companies, our research team just released
a new list of 5 stocks with the best chance to gain +100% or more in the year ahead.
These stocks feature:
Rock-solid fundamentals for long-term growth
Technical indicators that often signal explosive upside
While we can’t guarantee future performance, past editions of this report have delivered gains of +175%, +498%, even +673%¹.
Free access ends at MIDNIGHT TONIGHT.
Download the report now — 100% free
The Setup
Hims & Hers Health (NYSE: HIMS) sells direct-to-consumer healthcare subscriptions across categories like sexual health, dermatology, mental health, and wellness, using telehealth + fulfillment to remove friction.
The stock is around the low-$20s, down sharply from prior highs, and the next key checkpoint is whether the business can keep compounding subscribers and margins without leaning too hard on regulatory gray zones.
What Hims Actually Does
Think of Hims as a consumer acquisition + clinical workflow + pharmacy fulfillment engine:
Demand generation: brand + performance marketing pulls users in
Clinical routing: asynchronous visits / provider network for eligibility and scripts
Fulfillment: recurring shipments and refills drive repeat behavior
Category expansion: layering on new conditions raises LTV and reduces churn
This model can be powerful because subscription healthcare creates predictable repeat demand—as long as products stay compliant and outcomes stay credible.
Why The Stock Just Got Punched Again
The immediate issue is weight loss.
Reuters reported Hims said it would stop offering access to a compounded semaglutide pill after the FDA said it would take action related to the company’s $49 weight-loss pill.
Separately, reporting also cited that HHS General Counsel Mike Stuart said Hims was referred to the DOJ for potential violations tied to the Federal Food, Drug, and Cosmetic Act.
Here’s why that matters for investors:
Regulatory risk re-prices fast. Even if the core business is fine, the multiple compresses when regulators get involved.
Weight-loss was becoming a sentiment pillar. Investors were starting to model Hims as a “GLP-1 distribution platform.” This event forces a reset.
Trust is the product. In consumer healthcare, compliance and credibility aren’t side quests—they’re the brand moat.
Poll: You can time-travel to buy ONE thing at launch price. What do you pick?
Hidden Source (Sponsored)
While President Trump's official salary is $400,000 per year... his tax returns reveal he's been collecting up to $250,000 PER MONTH from one hidden source.
Until recently, most Americans couldn't touch the type of investment that makes up this investment.
But thanks to Executive Order 14330, that just changed. If you love investing in disruptive new companies...
Discover how to invest in the fund Trump uses to collect this income
The Bull Case
1) The core engine may still be intact
If the majority of revenue is still coming from established categories (and not the newest weight-loss push), then this can be a contained problem: remove the product, take the hit, keep compounding the base.
2) Pulling the product quickly could limit longer-term damage
It’s not good that it happened, but stopping can be better than fighting. The faster Hims moves away from anything regulators frame as “copycat,” the quicker the market can go back to underwriting the recurring model.
3) The platform is built for new products
Even without compounded GLP-1s, Hims can still win by expanding: diagnostics, personalization, chronic categories, and higher-retention services—anything that increases repeat purchasing without regulatory fragility.
4) If growth stays strong, valuation can recover without “hero narratives”
A lot of the upside case doesn’t require a massive return to hype. It just requires the company to prove that growth and margins are durable without pushing into legal risk.
Want to make sure you never miss a stock recommendation?
Elite Trade Club now offers text alerts — so you get trending stocks and market-moving news sent straight to your phone before the bell. Email’s great. Texts are faster.
The Bear Case
1) Regulatory overhang can linger
A DOJ referral is not something markets shrug off quickly. Even if nothing material comes of it, it can hang over the story and pressure the multiple.
2) Weight-loss may have been a bigger driver than investors realized
If demand for GLP-1-related offerings was becoming the marginal growth accelerator, pulling the product can slow momentum and force higher marketing spend elsewhere.
3) Category expansion gets harder when scrutiny rises
Once regulators are watching, every new launch gets interpreted through a harsher lens. That can slow speed-to-market and reduce “option value” in the business model.
4) Reputation risk is real in healthcare
Even if the product was legal under certain circumstances, the public framing (“copycat,” “illegal,” “crackdown”) can raise churn and acquisition costs.
Defensive Demand (Sponsored)
The world is rapidly shifting to cashless systems, with countries like China leading the way.
As the U.S. rolls out FEDNOW, it’s clear that convenience could come at a steep price—your freedom.
With digital currencies, those who control the ledger control your ability to speak, transact, and live freely.
Stay informed and safeguard your future.
Download our guide on CBDCs and protect your wealth.
What I’d Watch Next
If you’re tracking Hims as a “repair story,” keep it simple:
Revenue mix: how dependent was growth on weight loss versus core categories?
CAC efficiency: do customer acquisition economics worsen after the headline?
Regulatory language: do they tighten marketing claims and product positioning meaningfully?
Feb 23 earnings narrative: are they guiding confidently, or defensively? (Watch tone more than just numbers.)
Product roadmap quality: new categories that add retention without regulatory landmines.
My Take
This is the kind of headline that can knock a stock down more than the fundamentals deserve, but it also exposes the key question investors must answer:
Is Hims a durable subscription healthcare platform… or a growth story that needs regulatory edge to stay exciting?
The optimistic read is that weight loss was an add-on, not the foundation—and the platform can keep scaling through safer categories. The cautious read is that the market was starting to price Hims like a GLP-1 winner, and this forces a full narrative reset, with legal and compliance risk now firmly in the foreground.
That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.
Best Regards,
— Adam Garcia
Elite Trade Club
Click here to get our daily newsletter straight to your cell for free.
P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.
